1646 related articles for article (PubMed ID: 20546737)
1. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
2. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
3. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
4. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel.
Bahrami J; Yusta B; Drucker DJ
Gastroenterology; 2010 Jun; 138(7):2447-56. PubMed ID: 20226187
[TBL] [Abstract][Full Text] [Related]
5. A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes.
Robertson K; Lu Y; De Jesus K; Li B; Su Q; Lund PK; Liu JL
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E928-38. PubMed ID: 18270301
[TBL] [Abstract][Full Text] [Related]
6. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
9. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
10. Native pancreatic alpha-cell adaptation in streptozotocin-induced diabetic primates: importance for pig islet xenotransplantation.
Dufrane D; Maillart JF; Aouassar N; Goebbels RM; Guiot Y; Gianello P
Xenotransplantation; 2009; 16(3):152-63. PubMed ID: 19566655
[TBL] [Abstract][Full Text] [Related]
11. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
13. Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted.
Rotondo A; Amato A; Baldassano S; Lentini L; Mulè F
Peptides; 2011 Aug; 32(8):1587-92. PubMed ID: 21771622
[TBL] [Abstract][Full Text] [Related]
14. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
15. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.
Yusta B; Holland D; Koehler JA; Maziarz M; Estall JL; Higgins R; Drucker DJ
Gastroenterology; 2009 Sep; 137(3):986-96. PubMed ID: 19523469
[TBL] [Abstract][Full Text] [Related]
16. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
17. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.
Baldassano S; Amato A; Cappello F; Rappa F; Mulè F
J Endocrinol; 2013 Apr; 217(1):11-20. PubMed ID: 23308022
[TBL] [Abstract][Full Text] [Related]
19. Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice.
Winzell MS; Magnusson C; Ahrén B
Metabolism; 2007 Jan; 56(1):122-8. PubMed ID: 17161234
[TBL] [Abstract][Full Text] [Related]
20. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1.
Speck M; Cho YM; Asadi A; Rubino F; Kieffer TJ
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E923-32. PubMed ID: 21304061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
